Ajanta Pharma Ltd

Industry: Pharmaceuticals - Indian – Formulations

Ajanta Pharma Limited (APL) is an Indian multinational,
engaged in development, manufacturing and marketing of
pharmaceutical formulations. It has presence in India, USA
and about 30 Emerging countries including Africa,
Philippines, Rest of Asia, Middle East and CIS. Established in
1973.

Headquarters Mumbai, Maharashtra, India.

Key people Yogesh Agrawal, Managing Director.

Rajesh Agrawal, Joint Managing Director

Financial Overview
Mar 17 Mar 16 Mar 15

Market Capitalisation (in 15,491.52 12,412.58 10,777.04

crores)
Debt-Equity Ratio 0.03 0.07 0.15
ROCE (%) 47.39 54.83 58.62

Company Overview
Ajanta Pharma is a speciality pharmaceutical company,
Engaged in the development, manufacture and marketing
Of quality finished dosages in domestic and international
Markets. Its business includes Branded Generics in emerging
Markets of Asia and Africa, Generics in the developed markets
Of USA and Institution sales. It employs nearly 7,000 people
Worldwide and its products are sold in more than 30 countries.

Operational Highlights
 Entered the elite club of Fortune 500 Indian companies
 Turnover crossed 2,000 cr.
 Profit crossed 500 cr.
 Commissioned 1st phase at Guwahati manufacturing plant
 US FDA completes inspection at Paithan & Dahej plant
 Without any major observation
 Enhanced R&D spend to fuel the growth.
 Domestic business contributed 32% whereas exports
contributed 68% of the total revenue.

Future plans and growth

We are planning with a global mindset with focus on

specific markets, where we can be a meaningful player.

We are preparing ourselves to deliver effective

solutions that matter in the global healthcare landscape.
We are performing to build a sustainable
business, which creates value for all stakeholders.
The country-specific and product-specific model of
business is augmenting well to enhance market share in
international markets. We have over 1,400 product
registrations in hand and equal number under approval.
Thus, the investment in facilities, R&D and new products
is fueling future growth plan

Strengths
 Employees 6,500+ for the year ended 31st March
2017.
 Team From 28 different nationalities.
 R&D Scientists 800+ for the year ended 31st
March 2017.

Weekness

 To be present in the right markets with differentiated,

difficult-to-produce products has been designed to
create impact and optimize opportunities across
geographies.

 No significant or material orders have been passed

against the Company by the regulators, courts or
tribunals, which impacts the going concern status and
company’s operations in future.
PEER COMPARISION

Symbol AJANTPHARM FDC SYNGENE LUPIN

Fundamentals
Face Value 2.00 1.00 10.00 2.00
LTP 1,200.55 172.80 451.00 937.85
% change -1.23 1.05 0.33 -1.69
Traded Value 1,773.51 64.76 211.82 17,246.70
Traded Volume 1,46,362 37,498 47,190 18,34,424
VWAP 1,211.73 172.71 448.87 940.17
Ratio Analysis

Ex-Date 23-JUN-17 08-AUG-17 20-JUL-17 24-JUL-17

ANNUAL
ANNUAL
GENERAL
ANNUAL GENERAL DIVIDEND -
MEETING/DI
Corporate Action GENERAL MEETING/DIVI RS 1/- PER
VIDEND - RS
MEETING DEND - RS 2.25 SHARE
7.50 PER
PER SHARE
SHARE

Risk Profile

Qty. Traded 1,46,362 37,498 47,190 18,34,424

Deliverable Qty. 44,075 29,602 22,091 12,28,272
%Delivery Qty. to
30.11 78.94 46.81 66.96
Traded Qty
Security VaR 7.02 4.16 6.87 6.61
VaR Margin 7.50 7.50 7.50 7.50
Applicable Margin Rate 12.50 12.50 12.50 12.50
Extreme Loss Rate 5.00 5.00 5.00 5.00